-
1.发明授权Monoclonal antibodies specific for protease nexin-1 and puriciation of protease nexin-1 using monoclonal antibodies 失效使用单克隆抗体对蛋白酶nexin-1特异的单克隆抗体和蛋白酶nexin-1的纯化
公开(公告)号：US5134076A
公开(公告)日：1992-07-28
申请号：US249787
申请日：1988-09-27
CPC分类号： C07K14/8121 , C07K16/38 , A61K38/00
摘要： Monoclonal antibodies having a specificity for protease nexin-1 are described. Preferably an antibody has specificity to the reactive protease-binding site. The antibody is used in the affinity purification of PN-1 to produce large quantities of substantially pure PN-1, free of other biologically active molecules. Over a 2000-fold purification of a crude preparation of PN-1 may be obtained. The affinity-purified PN-1 is suitable for use in pharmacological preparations used in the treatment of neurological disease associated with serine protease-mediated inhibition of regenerative processes.
摘要翻译： 描述了对蛋白酶nexin-1具有特异性的单克隆抗体。 优选地，抗体对反应性蛋白酶结合位点具有特异性。 该抗体用于亲和纯化PN-1以产生大量基本上纯的PN-1，其不含其他生物活性分子。 可以获得2000倍以上的PN-1粗制品的纯化。 亲和纯化的PN-1适用于用于治疗与丝氨酸蛋白酶介导的再生过程抑制相关的神经疾病的药理学制剂。
-
公开(公告)号：US5213962A
公开(公告)日：1993-05-25
申请号：US924417
申请日：1992-07-30
IPC分类号： C12P21/08 , G01N33/573 , G01N33/68 , G01N33/86
CPC分类号： G01N33/6896 , G01N33/573 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed. These uses include the treatment and prevention of amyloid plaques in Alzheimer's disease and Down's Syndrome
摘要翻译： 公开了蛋白酶Nexin-2和β淀粉样蛋白前体蛋白的免疫纯化。 还公开了检测蛋白酶Nexin-2的方法以及这些方法在诊断阿尔茨海默病和其他病症中的用途。 此外，公开了包括蛋白酶Nexin-2或其修饰形式的药物制剂。 还公开了药物制剂的医疗用途。 这些用途包括治疗和预防阿尔茨海默病和唐氏综合征中的淀粉样斑块
-
3.发明授权Monoclonal antibody produced against native .beta.amyloid precursor protein 失效针对天然β淀粉样蛋白前体蛋白产生单克隆抗体
公开(公告)号：US5427931A
公开(公告)日：1995-06-27
申请号：US56423
申请日：1993-04-27
IPC分类号： C12P21/08 , G01N33/573 , G01N33/68 , G01N33/86 , A61K39/395
CPC分类号： G01N33/6896 , G01N33/573 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of .beta.APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of .beta.APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of .beta.APP in CSF, down to a total concentration of the secreted forms of .beta.APP of 3.75 .mu.g/ml or lower.
摘要翻译： 公开了单克隆抗体和产生抗体的杂交瘤。 针对beta APP的天然分泌形式的抗原产生抗体。 抗体的特征在于，抗体特异性结合已经生长了神经母细胞瘤细胞的培养基中的至少一种蛋白质。 该蛋白质在非还原性聚丙烯酰胺凝胶电泳中共同迁移，并从人成纤维细胞培养物中分离出PN-2。 抗体的其他特征是抗体特异性结合PN-2和分泌形式的缺乏Kunitz型抑制剂结构域的βAPP，抗体选择性地结合神经炎斑块，并且抗体足够敏感以检测分泌形式 βAPP在CSF中，分泌形式的APP的总浓度为3.75μg/ ml或更低。
-
公开(公告)号：US5270165A
公开(公告)日：1993-12-14
申请号：US779070
申请日：1991-10-15
IPC分类号： A61K39/395 , C12N5/10 , C12N9/99 , C12N15/02 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/645 , C12R1/91 , G01N33/53 , G01N33/573 , G01N33/577 , G01N33/68 , G01N33/86
CPC分类号： G01N33/573 , G01N33/6896 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample fromNOTICE OF GOVERNMENT SUPPORTThis invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.
摘要翻译： 公开了一种在哺乳动物中诊断淀粉样蛋白的脑血管沉积的疾病，包括阿尔茨海默氏病，淀粉样变性 - 荷兰型和其他淀粉样变性的遗传性脑出血，其中获得脑脊液样品，对单克隆抗体的免疫反应性水平 测量样品中针对天然PN-2 /βAPP或其他淀粉样蛋白前体蛋白产生的抗体，并将该测量水平与来自正常受试者的样品中针对该抗体的免疫反应性水平进行比较。 来自哺乳动物样本的较低水平表明该疾病的可能性。
-
5.发明授权公开(公告)号：US08815794B2
公开(公告)日：2014-08-26
申请号：US13061433
申请日：2009-08-28
IPC分类号： A61K38/10
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1709 , A61K38/1716 , C07K14/4711 , C07K14/4713 , G01N33/6896 , G01N2500/00
摘要： In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibril lization of peptides implicated in the amyloidoses, especially the amyloid-beta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.
摘要翻译： 在其各种实施方案中，本发明提供了髓鞘碱性蛋白和干扰与淀粉样变性牵涉的肽的原纤维化的片段，特别是与阿尔茨海默病（“AD”）和脑淀粉样血管病（“CAA”）相关的淀粉样蛋白-β肽， ）。 一些实施例提供了识别附加干扰片段的方法。 其他提供识别调节干扰物质的方法。 其它实施方案提供了通过施用髓鞘碱性蛋白或其片段来预防淀粉样变，特别是AD和CAA的方法。
-
6.发明申请TREATMENT OF AMYLOIDOSES USING MYELIN BASIC PROTEIN AND FRAGMENTS THEREOF 有权使用MYELIN基础蛋白及其片段处理淀粉样蛋白公开(公告)号：US20110294740A1
公开(公告)日：2011-12-01
申请号：US13061433
申请日：2009-08-28
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1709 , A61K38/1716 , C07K14/4711 , C07K14/4713 , G01N33/6896 , G01N2500/00
摘要： In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibril lization of peptides implicated in the amyloidoses, especially the amyloid-beta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.
摘要翻译： 在其各种实施方案中，本发明提供了髓鞘碱性蛋白和干扰与淀粉样变性牵涉的肽的原纤维化的片段，特别是与阿尔茨海默病（“AD”）和脑淀粉样血管病（“CAA”）相关的淀粉样蛋白-β肽， ）。 一些实施例提供了识别附加干扰片段的方法。 其他提供识别调节干扰物质的方法。 其它实施方案提供了通过施用髓鞘碱性蛋白或其片段来预防淀粉样变，特别是AD和CAA的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.034 秒)